These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35597248)

  • 1. The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study.
    Dodd PJ; Mafirakureva N; Seddon JA; McQuaid CF
    Lancet Glob Health; 2022 Jul; 10(7):e1034-e1044. PubMed ID: 35597248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Korotych O; Achar J; Gurbanova E; Hovhannesyan A; Lomtadze N; Ciobanu A; Skrahina A; Dravniece G; Kuksa L; Rich M; Khachatryan N; Germanovych M; Kadyrov A; Terleieva I; Akhundova I; Adenov M; Durdyeva M; Kiria N; Parpieva N; Yatskevich N; Jumayev R; Nurov R; Diktanas S; Vilc V; Migliori GB; Yedilbayev A
    Lancet Infect Dis; 2024 Oct; 24(10):1151-1161. PubMed ID: 38880112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
    Seddon JA; Garcia-Prats AJ; Purchase SE; Osman M; Demers AM; Hoddinott G; Crook AM; Owen-Powell E; Thomason MJ; Turkova A; Gibb DM; Fairlie L; Martinson N; Schaaf HS; Hesseling AC
    Trials; 2018 Dec; 19(1):693. PubMed ID: 30572905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
    Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.
    Kendall EA; Hussain H; Kunkel A; Kubiak RW; Trajman A; Menzies R; Drain PK
    BMC Med; 2021 Dec; 19(1):315. PubMed ID: 34903214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study.
    Dodd PJ; Yuen CM; Becerra MC; Revill P; Jenkins HE; Seddon JA
    Lancet Glob Health; 2018 Dec; 6(12):e1329-e1338. PubMed ID: 30266570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis.
    Ryckman T; Weiser J; Gombe M; Turner K; Soni P; Tarlton D; Mazhidova N; Churchyard G; Chaisson RE; Dowdy DW
    Lancet Glob Health; 2023 Aug; 11(8):e1205-e1216. PubMed ID: 37474228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of community-based household tuberculosis contact management for children in Cameroon and Uganda: a modelling analysis of a cluster-randomised trial.
    Mafirakureva N; Tchounga BK; Mukherjee S; Tchakounte Youngui B; Ssekyanzi B; Simo L; Okello RF; Turyahabwe S; Kuate Kuate A; Cohn J; Vasiliu A; Casenghi M; Atwine D; Bonnet M; Dodd PJ
    Lancet Glob Health; 2023 Dec; 11(12):e1922-e1930. PubMed ID: 37918416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study.
    Dodd PJ; Sismanidis C; Seddon JA
    Lancet Infect Dis; 2016 Oct; 16(10):1193-1201. PubMed ID: 27342768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.
    von Gottberg A; Klugman KP; Cohen C; Wolter N; de Gouveia L; du Plessis M; Mpembe R; Quan V; Whitelaw A; Hoffmann R; Govender N; Meiring S; Smith AM; Schrag S;
    Lancet; 2008 Mar; 371(9618):1108-13. PubMed ID: 18359074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.
    Menzies NA; Allwood BW; Dean AS; Dodd PJ; Houben RMGJ; James LP; Knight GM; Meghji J; Nguyen LN; Rachow A; Schumacher SG; Mirzayev F; Cohen T
    Nat Commun; 2023 Oct; 14(1):6182. PubMed ID: 37794037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    ; Ahmad N; Ahuja SD; Akkerman OW; Alffenaar JC; Anderson LF; Baghaei P; Bang D; Barry PM; Bastos ML; Behera D; Benedetti A; Bisson GP; Boeree MJ; Bonnet M; Brode SK; Brust JCM; Cai Y; Caumes E; Cegielski JP; Centis R; Chan PC; Chan ED; Chang KC; Charles M; Cirule A; Dalcolmo MP; D'Ambrosio L; de Vries G; Dheda K; Esmail A; Flood J; Fox GJ; Fréchet-Jachym M; Fregona G; Gayoso R; Gegia M; Gler MT; Gu S; Guglielmetti L; Holtz TH; Hughes J; Isaakidis P; Jarlsberg L; Kempker RR; Keshavjee S; Khan FA; Kipiani M; Koenig SP; Koh WJ; Kritski A; Kuksa L; Kvasnovsky CL; Kwak N; Lan Z; Lange C; Laniado-Laborín R; Lee M; Leimane V; Leung CC; Leung EC; Li PZ; Lowenthal P; Maciel EL; Marks SM; Mase S; Mbuagbaw L; Migliori GB; Milanov V; Miller AC; Mitnick CD; Modongo C; Mohr E; Monedero I; Nahid P; Ndjeka N; O'Donnell MR; Padayatchi N; Palmero D; Pape JW; Podewils LJ; Reynolds I; Riekstina V; Robert J; Rodriguez M; Seaworth B; Seung KJ; Schnippel K; Shim TS; Singla R; Smith SE; Sotgiu G; Sukhbaatar G; Tabarsi P; Tiberi S; Trajman A; Trieu L; Udwadia ZF; van der Werf TS; Veziris N; Viiklepp P; Vilbrun SC; Walsh K; Westenhouse J; Yew WW; Yim JJ; Zetola NM; Zignol M; Menzies D
    Lancet; 2018 Sep; 392(10150):821-834. PubMed ID: 30215381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis.
    Bisson GP; Bastos M; Campbell JR; Bang D; Brust JC; Isaakidis P; Lange C; Menzies D; Migliori GB; Pape JW; Palmero D; Baghaei P; Tabarsi P; Viiklepp P; Vilbrun S; Walsh J; Marks SM
    Lancet; 2020 Aug; 396(10248):402-411. PubMed ID: 32771107
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.